Yao Z, Garmestani K, Wong K J, Park L S, Dadachova E, Yordanov A, Waldmann T A, Eckelman W C, Paik C H, Carrasquillo J A
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 10 Center Dr., Bethesda, MD 20892-1180, USA.
J Nucl Med. 2001 Oct;42(10):1538-44.
Monoclonal antibodies (mAbs) labeled with alpha-emitting radionuclides such as (211)At, (212)Bi, (213)Bi, and (212)Pb (which decays by beta-emission to its alpha-emitting daughter, (212)Bi) are being evaluated for their potential applications for cancer therapy. The fate of these radionuclides after cells are targeted with mAbs is important in terms of dosimetry and tumor detection.
In this study, we attached various radionuclides that result in alpha-emissions to T101, a rapidly internalizing anti-CD5 mAb. We then evaluated the catabolism and cellular retention and compared them with those of (125)I- and (111)In-labeled T101. T101 was labeled with (211)At, (125)I, (205,6)Bi, (111)In, and (203)Pb. CD5 antigen-positive cells, peripheral blood mononuclear cells (PBMNC), and MOLT-4 leukemia cells were used. The labeled T101 was incubated with the cells for 1 h at 4 degrees C for surface labeling. Unbound activity was removed and 1 mL medium added. The cells were then incubated at 37 degrees C for 0, 1, 2, 4, 8, and 24 h. The activity on the cell surface that internalized and the activity on the cell surface remaining in the supernatant were determined. The protein in the supernatant was further precipitated by methanol for determining protein-bound and non-protein-bound radioactivity. Sites of internal cellular localization of radioactivity were determined by Percoll gradient centrifugation.
All radiolabeled antibodies bound to the cells were internalized rapidly. After internalization, (205,6)Bi, (203)Pb, and (111)In radiolabels were retained in the cell, with little decrease of cell-associated radioactivity. However, (211)At and (125)I were released from cells rapidly ((211)At < (125)I) and most of the radioactivity in the supernatant was in a non-protein-bound form. Intracellular distribution of radioactivity revealed a transit of the radiolabel from the cell surface to the lysosome. The catabolism patterns of MOLT-4 cells and PBMNC were similar.
(211)At catabolism and release from cells were somewhat similar to that of (125)I, whereas (205,6)Bi and (203)Pb showed prolonged cell retention similar to that of (111)In. These catabolism differences may be important in the selection of alpha-radionuclides for radioimmunotherapy.
用发射α粒子的放射性核素如砹 - 211(²¹¹At)、铋 - 212(²¹²Bi)、铋 - 213(²¹³Bi)和铅 - 212(²¹²Pb,其通过β衰变产生发射α粒子的子体铋 - 212)标记的单克隆抗体(mAb)正在接受癌症治疗潜在应用的评估。就剂量测定和肿瘤检测而言,这些放射性核素在单克隆抗体靶向细胞后的归宿很重要。
在本研究中,我们将各种产生α发射的放射性核素连接到T101上,T101是一种快速内化的抗CD5单克隆抗体。然后我们评估了其分解代谢和细胞保留情况,并将它们与碘 - 125(¹²⁵I)和铟 - 111(¹¹¹In)标记的T101进行比较。T101用砹 - 211、碘 - 125、铋 - 205.6、铟 - 111和铅 - 203进行标记。使用CD5抗原阳性细胞、外周血单核细胞(PBMNC)和MOLT - 4白血病细胞。将标记的T101与细胞在4℃下孵育1小时进行表面标记。去除未结合的活性物质并加入1mL培养基。然后将细胞在37℃下孵育0、1、2、4、8和24小时。测定内化到细胞表面的活性以及上清液中留在细胞表面的活性。通过甲醇进一步沉淀上清液中的蛋白质以确定蛋白质结合和非蛋白质结合的放射性。通过Percoll梯度离心确定细胞内放射性的定位位点。
所有与细胞结合的放射性标记抗体均迅速内化。内化后,铋 - 205.6、铅 - 203和铟 - 111放射性标记保留在细胞中,细胞相关放射性几乎没有下降。然而,砹 - 211和碘 - 125迅速从细胞中释放(砹 - 211<碘 - 125),上清液中的大部分放射性呈非蛋白质结合形式。放射性的细胞内分布显示放射性标记从细胞表面转运到溶酶体。MOLT - 4细胞和PBMNC的分解代谢模式相似。
砹 - 211的分解代谢和从细胞中的释放与碘 - 125有些相似,而铋 - 205.6和铅 - 203显示出与铟 - 111相似的细胞内长时间保留。这些分解代谢差异在选择用于放射免疫治疗的α放射性核素时可能很重要。